950
Participants
Start Date
February 28, 2005
Primary Completion Date
October 31, 2006
Study Completion Date
October 31, 2006
Certolizumab pegol (CDP870)
Huntsville
Paradise Valley
La Jolla
San Diego
Denver
Danbury
Washington D.C.
Aventura
Ocala
Orlando
Sarasota
Tampa
Coeur d'Alene
Springfield
Wichita
Wheaton
St Louis
Lincoln
Charlotte
Cleveland
Dayton
Duncansville
Charleston
Austin
Dallas
San Antonio
Capital Federal
Córdoba
Camperdown
Coffs Harbour
Cotton Tree
Malvern
Shenton Park
Victoria Park
Westmead
Wooloongabba
Antwerp
Brussels
Liège
Merksem
Sijsele
Pleven
Sofia
Stara Zagora
Varna
Courtice
Hamilton
Kitchener
London
Mississauga
Montreal
Newmarket
Point Claire
Sainte-Foy
Toronto
Winnipeg
Valdivia
Santiago
Santiago
Temuco
Rijeka
Brno
Brno Bohunice
Ostrava Trebovice
Pilsen
Prague
Uherské Hradiště
Zlín
Afula
Haifa
Ramat Gan
Tel Aviv
Riga
Moscow
Saint Petersburg
Ivano-Frankivsk
Lead Sponsor
UCB Pharma
INDUSTRY